-
Clinical Background Factors as Predictors of the Efficacy of 5-Aminosalicylic Acid Suppositories in Patients with Ulcerative Colitis. Inflamm. Intest. Dis. Pub Date : 2023-08-10 Kazuhiko Uchiyama,Tomohisa Takagi,Katsura Mizushima,Kohei Asaeda,Mariko Kubota-Kajiwara,Takeshi Sugaya,Saori Kashiwagi,Yuki Minagawa,Yuma Hotta,Makoto Tanaka,Ken Inoue,Kazuhiro Katada,Kazuhiro Kamada,Takeshi Ishikawa,Hiroaki Yasuda,Hideyuki Konishi,Mitsuo Kishimoto,Yuji Naito,Yoshito Itoh
Introduction Although the efficacy of 5-aminosalicylic acid (ASA) suppositories for ulcerative colitis (UC) has been reported in many studies, many studies have also described poor adherence to 5-ASA suppository regimens. We aimed to identify the clinical background factors that influence adherence to 5-ASA suppositories to improve adherence and efficacy of the treatment. Methods We conducted a retrospective
-
Iron Deficiency Is Common after Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis. Inflamm. Intest. Dis. Pub Date : 2023-07-24 Ishaan Dharia,Taqwa Ahmed,Michael Plietz,Sergey Khaitov,Patricia Sylla,Alexander Greenstein,Marla C Dubinsky,Maia Kayal
Background Micronutrient deficiencies may occur after restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA) in patients with ulcerative colitis (UC), largely due to malabsorption and/or pouch inflammation. Objectives The objective of this study was to report the frequency of iron deficiency in patients with UC who underwent RPC with IPAA and identify associated risk factors. Methods
-
Associations between Pouchitis and Fecal Calprotectin after Restorative Proctocolectomy in Patients with Ulcerative Colitis. Inflamm. Intest. Dis. Pub Date : 2023-07-12 Motoi Uchino,Yuki Horio,Ryuichi Kuwahara,Kurando Kusunoki,Kentaro Nagano,Hiroki Ikeuchi
Introduction Recently, fecal calprotectin has been identified and used as an assessment tool for the confirmation of disease activity in ulcerative colitis. Although a meta-analysis suggested the usefulness of fecal calprotectin for the assessment of pouchitis, the number of participants was still insufficient. Therefore, we prospectively measured fecal calprotectin levels during pouchoscopy and analyzed
-
Usefulness of Serum Leucine-Rich Alpha-2 Glycoprotein as a Surrogate Marker of Small Bowel Mucosal Injury in Crohn's Disease. Inflamm. Intest. Dis. Pub Date : 2023-07-10 Takuto Saiki,Takehiro Torisu,Akira Harada,Yu Kajiya,Yoshiaki Taniguchi,Shinji Morisaki,Junji Umeno,Hiroshi Suekane,Takanari Kitazono
Introduction Although the importance of mucosal healing has been suggested in Crohn's disease, it is difficult to repeat endoscopy, especially for the entire small bowel. Recently, serum leucine-rich alpha-2 glycoprotein (LRG) has been used as a surrogate marker of endoscopy. However, few studies have investigated a correlation between LRG and mucosal injury of the entire small bowel. Methods We retrospectively
-
Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction. Inflamm. Intest. Dis. Pub Date : 2023-06-21 Geert D'Haens,Ekaterina Safroneeva,Helen Thorne,Raphaël Laoun
Introduction High-strength mesalazine formulations play an important role in providing a convenient option to increase the dose in ulcerative colitis (UC) patients and therefore avoiding the switch to another therapeutic class. Higher doses of mesalazine may be required during periods of remission in order to prevent relapse. Aim The aim of the study was to investigate clinical outcomes of three mesalazine
-
Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis. Inflamm. Intest. Dis. Pub Date : 2023-06-14 Genta Uchida,Masanao Nakamura,Takeshi Yamamura,Keiko Maeda,Tsunaki Sawada,Eri Ishikawa,Kazuhiro Furukawa,Tadashi Iida,Yasuyuki Mizutani,Kentaro Yamao,Takuya Ishikawa,Yoji Ishizu,Takashi Honda,Masatoshi Ishigami,Hiroki Kawashima
Introduction Ustekinumab (UST) has been approved for the treatment of moderate-to-severe ulcerative colitis (UC). Real-world data showing the effectiveness and safety of UST are necessary to confirm the results of clinical trials for applicability in daily clinical practice. Although some studies have reported real-world evidence of UST, only few studies have confirmed its effectiveness in the real
-
Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey. Inflamm. Intest. Dis. Pub Date : 2023-05-12 Xavier Hébuterne,Stephan R Vavricka,Helen C Thorne,Lara MacKenzie-Smith,Raphaël Laoun,Johan Burisch
Introduction Patient adherence is a major challenge for the successful management of any chronic disease, and ulcerative colitis (UC) is no exception. Patient adherence is closely related to patient preference of medication and formulation used. Aim The aim of this study was to investigate patient and physician perspectives around UC treatment preference. Methods This study was conducted in France
-
Optimal Use of Serum Leucine-Rich Alpha-2 Glycoprotein as a Biomarker for Small Bowel Lesions of Crohn's Disease. Inflamm. Intest. Dis. Pub Date : 2023-05-11 Kunio Asonuma,Taku Kobayashi,Nao Kikkawa,Masaru Nakano,Shintaro Sagami,Hiromu Morikubo,Yusuke Miyatani,Aya Hojo,Tomohiro Fukuda,Toshifumi Hibi
Introduction A large proportion of small bowel lesions in Crohn's disease (CD) may exist beyond the reach of ileocolonoscopy and there is no gold standard imaging modality to screen them, suggesting the need for optimal biomarkers. We aimed to compare the usefulness of C-reactive protein (CRP), faecal calprotectin (FC), and leucine-rich alpha-2 glycoprotein (LRG) in determining small bowel lesions
-
Smoking is not an Independent Risk Factor for Surgery in Patients with Crohn’s Disease on Biologic Therapy Inflamm. Intest. Dis. Pub Date : 2023-04-15 Saleem Halablab, Ayman Alrazim, Christian Sadaka, Hasan Slika, Nour Adra, Wissam Ghusn, Manar Shmais, Ala I. Sharara
Introduction: The development and course of inflammatory bowel disease (IBD) appears to be influenced by environmental factors. Particularly, smoking has been shown to assume a harmful role in Crohn’s disease (CD) and a protective role in ulcerative colitis (UC). This study aims to examine the effect of smoking on need for surgery in patients with moderate to severe Crohn’s disease (CD) receiving biologic
-
Construction of an explanatory model for quality of life in outpatients with ulcerative colitis Inflamm. Intest. Dis. Pub Date : 2023-04-12 Miho Takahashi, Maya Nunotani, Nobuo Aoyama
Abstract Introduction: To date, no studies have reported explanatory models of health-related quality of life (HRQoL) in patients with ulcerative colitis. Therefore, this study aimed to examine HRQoL and its related factors in outpatients with ulcerative colitis to construct an explanatory model. Methods: We conducted a cross-sectional survey at a clinic in Japan. The HRQoL was evaluated using the
-
A Systematic Review of Self-Management Interventions for Patients with Inflammatory Bowel Disease Inflamm. Intest. Dis. Pub Date : 2023-03-27 Masami Iizawa, Lisa Hirose, Maya Nunotani, Mikiko Nakashoji, Ai Tairaka, Jovelle Fernandez
Introduction: Previous studies have reported the effectiveness of inflammatory bowel disease (IBD) self-management. However, it is unclear which types of self-management interventions are effective. We conducted a systematic literature review to clarify the status and efficacy of self-management interventions for IBD. Methods: Searches were performed in databases including Embase, Medline, and Cochrane
-
-
A Regional Survey of Awareness of Inflammatory Bowel Disease among the Saudi Population Inflamm. Intest. Dis. Pub Date : 2023-02-15 Yaser Khalid Meeralam, Adnan Al Zanabgi, Mahmoud Mosli, Yosif Qari, Mona Al Saedi, Abdulaziz Tashkhandi, Mahmoud Eliouny, Abdulwahab Neyazi, Ghadeer Al Hazmi, Mohammed Kareem Shariff
Introduction: Inflammatory bowel disease (IBD) is common worldwide, including the gulf region. Early diagnosis of IBD can improve patients' outcomes. However, early diagnosis is dependent on patients' awareness of the disease to seek medical advice. This study aims to survey the awareness of IBD in the the general population of the western region of Saudi Arabia. Methods: A questionnaire about Crohn's
-
The impact of concomitant ulcerative colitis on the clinical course in patients with primary sclerosing cholangitis: an investigation using a nationwide database in Japan Inflamm. Intest. Dis. Pub Date : 2023-02-01 Rintaro Moroi, Kota Yano, Kunio Tarasawa, Yusuke Shimoyama, Takeo Naito, Hisashi Shiga, Shin Hamada, Yoichi Kakuta, Kiyohide Fushimi, Kenji Fujimori, Yoshitaka Kinouchi, Atsushi Masamune
Introoduction: Primary sclerosing cholangitis (PSC) is a rare disease, especially in Asian countries. PSC often develops during ulcerative colitis (UC). Little is known about the severity of PSC in patients with UC. Thus, this study aimed to investigate the impact of concomitant UC on the clinical course of patients with PSC using a nationwide database in Japan. Methods: We collected data on patients
-
Molecular basis of intestinal fibrosis in inflammatory bowel disease Inflamm. Intest. Dis. Pub Date : 2022-12-01 Akira Andoh, Atsushi Nishida
Background: Intestinal fibrosis in Crohn’s disease (CD) is considered to be irreversible and induces persistent luminal narrowing and strictures. In the past decades, substantial advances have been made in the understanding of the cellular and molecular mechanisms underlying intestinal fibrosis in inflammatory bowel disease (IBD). Summary: Intestinal fibrosis is typically associated with mesenchymal
-
Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-week Results from Post-marketing Surveillance in Japan Inflamm. Intest. Dis. Pub Date : 2022-11-18 Shiro Nakamura, Teita Asano, Yoshihito Tanaka, Kanami Sugimoto, Shinichi Yoshigoe, Yasuo Suzuki
Introduction: Real-world evidence for the effectiveness and safety of golimumab (GLM) in patients with ulcerative colitis (UC) is limited. The aim of this study was to investigate the 52-week effectiveness and safety of GLM treatment for UC. Methods: This prospective, multicentre, post-marketing surveillance study is conducted in 393 patients with UC in Japan (UMIN000027542). Clinical remission (partial
-
Early phase partial Mayo score following golimumab treatment is associated with endoscopic improvement at 1-year in ulcerative colitis; A post hoc analysis of PURSUIT-J randomized controlled trial Inflamm. Intest. Dis. Pub Date : 2022-08-02 Katsumasa Nagano, Yuya Imai, Yoshifumi Ukyo, Taku Kobayashi, Seiji Yokoyama
Objective: Golimumab (GLM) is an anti-tumor necrosis factor-alpha antibody therapy for moderately to severely active ulcerative colitis (UC). Endoscopic improvement is considered one of UC treatment's main goals, and earlier prediction of future endosopic improvement has clinical implications. We retrospectively analyzed data from the PURSUIT-J, a phase III randomized controlled trial evaluating the
-
-
Therapy patterns and surveillance measures of Inflammatory Bowel Disease patients beyond disease-related hospitalization: a claims-based cohort study Inflamm. Intest. Dis. Pub Date : 2022-04-27 Caroline Baehler, Beat Brüngger, Eva Blozik, Stephan R. Vavricka, Alain M. Schoepfer
Introduction: Medical care and surveillance of inflammatory bowel disease (IBD) patients has been shown to be far from satisfactory. Data on therapy patterns and surveillance measures in IBD patients are scarce. We, therefore, aimed to compare the therapy patterns and surveillance management of IBD patients in the year before and after IBD-related hospitalization. Methods: We examined medical therapy
-
Title Page/Table of Contents Inflamm. Intest. Dis. Pub Date : 2022-01-18
Inflamm Intest Dis 2022;7:1–3
-
Author Index Vol. 7, No. 1, 2022 Inflamm. Intest. Dis. Pub Date : 2022-01-18
Inflamm Intest Dis 2022;7:69
-
Subject Index Vol. 7, No. 1, 2022 Inflamm. Intest. Dis. Pub Date : 2022-01-18
Inflamm Intest Dis 2022;7:70
-
Acknowledgement to Reviewers Inflamm. Intest. Dis. Pub Date : 2021-12-09
Inflamm Intest Dis 2021;6:225
-
-
-
Diagnostic Delay of Inflammatory Bowel Disease Is Significantly Higher in Public versus Private Health Care System in Mexican Patients Inflamm. Intest. Dis. Pub Date : 2021-12-06 Jesús K. Yamamoto-Furusho, Norma N. Parra-Holguín
Introduction: Inflammatory bowel disease (IBD) includes ulcerative colitis (UC) and Crohn’s disease (CD) characterized by a fluctuating course with periods of clinical activity and remission. No previous studies have demonstrated the frequency of delay at diagnosis and its associated factors in Mexico and Latin America. The aim of this study was to evaluate diagnostic delay of IBD in the last 4 decades
-
Implementing Collaborative Care Management of Behavioral Health for Patients with Inflammatory Bowel Disease Inflamm. Intest. Dis. Pub Date : 2021-12-02 Christine Beran, Nathaniel A. Sowa, Millie D. Long, Hans H. Herfarth, Spencer D. Dorn
Background Individuals with inflammatory bowel disease (IBD) are up to twice as likely to suffer from anxiety and/or depression. Collaborative care management (CoCM) is an evidenced-based approach to treating behavioral health disorders that has proven effective for a range of conditions in primary care and some specialty settings. This model involves a team-based approach, with care delivered by a
-
Impact of Diagnostic Delay on Disease Course in Pediatric Versus Adult-onset Patients with Ulcerative Colitis: Data from the Swiss IBD Cohort Inflamm. Intest. Dis. Pub Date : 2021-11-18 Alain M. Schoepfer, Vu Dang Chau Tran, Jean-Benoit Rossel, Christiane Sokollik, Johannes Spalinger, Ekaterina Safroneeva, Thea von Graffenried, Sebastien Godat, Dieter Hahnloser, Stephan R. Vavricka, Christian Braegger, Andreas Nydegger, on behalf of the Swiss IBD Cohort Study group
Introduction: Given the lack of data we aimed to assess the impact of the length of diagnostic delay on natural history of ulcerative colitis in pediatric (diagnosed <18 years) and adult patients (diagnosed ≥18 years). Methods: Data from the Swiss Inflammatory Bowel Disease cohort study were analyzed. Diagnostic delay was defined as interval between the first appearance of UC-related symptoms until
-
Stopping anti-TNF in CD remitters: pros and cons Inflamm. Intest. Dis. Pub Date : 2021-11-17 Edouard Louis
Background: There is no cure for Crohn’s disease. Available treatments and treatment strategies, particularly anti-TNF, allow to heal intestinal lesions and maintain steroid-free remission in a subset of patients. Having in mind the remitting/relapsing nature of the disease, patients and health care providers often ask themselves whether the treatment could be withdrawn. Several studies have demonstrated
-
Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use Inflamm. Intest. Dis. Pub Date : 2021-11-17 Danielle Bargo, Theo Tritton, Joseph C. Cappelleri, Marco DiBonaventura, Timothy W. Smith, Takanori Tsuchiya, Sean Gardiner, Irene Modesto, Tim Holbrook, Daniel Bluff, Taku Kobayashi
Objective: The aim of the study was to improve understanding of adherence and persistence to biologics, and their association with health-care resource utilization (HCRU), in Japanese patients with moderate to severe ulcerative colitis (UC). Methods: Data were from Medical Data Vision, a secondary care administrative database. A retrospective, longitudinal cohort analysis was conducted of data from
-
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Noninvasive Predictors of the Therapeutic Outcomes of Systemic Corticosteroid Therapy in Ulcerative Colitis Inflamm. Intest. Dis. Pub Date : 2021-11-16 Katsuya Endo, Tomonori Satoh, Yuki Yoshino, Shiho Kondo, Yoko Kawakami, Tomofumi Katayama, Yoshiteru Sasaki, Atsuko Takasu, Takayuki Kogure, Morihisa Hirota, Takayoshi Meguro, Kennichi Satoh
Introduction: Predictive biomarkers for the therapeutic outcome of induction therapy with systemic corticosteroid for active ulcerative colitis (UC) have not been established. This study aimed to investigate whether neutrophil-to-lymphocyte ratio (NLR) and/or platelet-to-lymphocyte ratio (PLR) can be predictive biomarkers for the therapeutic outcomes of systemic corticosteroid therapy in UC. Methods:
-
DEDICATED PSYCHIATRY CLINIC FOR INFLAMMATORY BOWEL DISEASE PATIENTS HAS A POSITIVE IMPACT ON DEPRESSION SCORES Inflamm. Intest. Dis. Pub Date : 2021-11-10 Kaleb Bogale, Sanjay Yadav, August Stuart, Allen R. Kunselman, Shannon Dalessio, Nana Bernasko, Andrew Tinsley, Kofi Clarke, Emmanuelle Williams, Matthew D. Coates
BACKGROUND: Psychiatric disorders, including anxiety and depression, are significantly more common in patients with inflammatory bowel disease. We established an integrated psychiatry clinic for IBD patients at our tertiary center IBD clinic to provide patients with critical, but frequently unavailable, coordinated mental health services. We undertook this study to evaluate the impact of this service
-
Behcet’s Disease: An In-depth Review About Pathogenesis, Gastrointestinal Manifestations And Management Inflamm. Intest. Dis. Pub Date : 2021-11-04 Anthony Nguyen, Shubhra Upadhyay, Muhammad Ali Javaid, Abdul Moiz Qureshi, Shahan Haseeb, Nismat Javed, Christopher Cormier, Asif Farooq, Abu Baker Sheikh
Background: Behcet’s Disease (BD) is a complex inflammatory vascular disorder that follows a relapsing-remitting course with diverse clinical manifestations. The prevalence of the disease varies throughout the globe and targets different age groups. There are many variations of BD, however, intestinal BD is not only more common but has many signs and symptoms. Summary: BD is a relapsing-remitting inflammatory
-
Mucosal Healing in Crohn’s Disease: Bull’s Eye or Bust? “The Pro Position” Inflamm. Intest. Dis. Pub Date : 2021-11-03 Neil O’Moráin, Jayne Doherty, Roisin Stack, Glen A. Doherty
Background: Crohn’s disease (CD) is a chronic inflammatory disorder affecting the gastrointestinal tract with disease behaviour based on the depth and severity of mucosal injury. Cumulative injury can result in complications including stricture formation and penetrating complications which often require surgical resection of diseased segments of the intestine resulting in significant morbidity. Accurate
-
Mucosal Healing in Crohn’s Disease: Bull’s Eye or Bust? The “Relative” Con Position Inflamm. Intest. Dis. Pub Date : 2021-10-20
Background: Crohn’s disease is a progressive inflammatory bowel disease. Persistent untreated inflammation can cumulatively result in bowel damage in the form of strictures, fistulas, and fibrosis, which can ultimately result in the need for major abdominal surgery. Mucosal healing has emerged as an attractive, yet ambitious goal in the hope of preventing long-term complications. Summary: Clinical
-
Mucosal Healing in Crohn’s Disease: Bull’s Eye or Bust? The “Relative” Con Position Inflamm. Intest. Dis. Pub Date : 2021-10-20 Mahmoud Mosli,Turki Alameel,Ala I. Sharara
Background: Crohn’s disease is a progressive inflammatory bowel disease. Persistent untreated inflammation can cumulatively result in bowel damage in the form of strictures, fistulas, and fibrosis, which can ultimately result in the need for major abdominal surgery. Mucosal healing has emerged as an attractive, yet ambitious goal in the hope of preventing long-term complications. Summary: Clinical
-
Transmural Inflammation, Ileitis, and Granulomas at the Time of Proctocolectomy in Patients with Ulcerative Colitis Do Not Predict Future Development of Pouchitis Inflamm. Intest. Dis. Pub Date : 2021-10-07 Edward L. Barnes, Joshua Hudson, Scott Esckilsen, Bharati Kochar, Michael D. Kappelman, Millie D. Long, Mark Koruda, Robert S. Sandler, Hans H. Herfarth
Background: The most common complication following ileal pouch-anal anastomosis (IPAA) in patients with ulcerative colitis (UC) is pouchitis. Our study aimed to investigate the relationship between histopathologic findings of ileitis, granuloma, or transmural inflammation on the colectomy specimen of patients with clinically and endoscopically diagnosed UC and the development of pouchitis within the
-
Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability Inflamm. Intest. Dis. Pub Date : 2021-09-28 Elise E. Crame, Joanne M. Bowen, Kate R. Secombe, Janet K. Coller, Maxime François, Wayne Leifert, Hannah R. Wardill
Introduction: Toll-like receptor 4 (TLR4) is a highly conserved immunosurveillance protein of innate immunity, displaying well-established roles in homeostasis and intestinal inflammation. Current evidence shows complex relationships between TLR4 activation, maintenance of health, and disease progression; however, it commonly overlooks the importance of site-specific TLR4 expression. This omission
-
Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis Inflamm. Intest. Dis. Pub Date : 2021-09-07 Mahmoud Mosli, Sameer Alawadhi, Fuad Hasan, Antoine Abou Rached, Faisal Sanai, Silvio Danese
Objectives: Despite the recent findings of the rising incidence of inflammatory bowel disease (IBD) in Arab countries, there are limited data on the characteristics of IBD patients and the disease course in the Arab world. This systematic review aimed to investigate the incidence and epidemiology of IBD in the Arab world. Material and Methods: We conducted a systematic literature review that utilized
-
Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How? Inflamm. Intest. Dis. Pub Date : 2021-09-06 Manar Shmais, Miguel Regueiro, Jana G. Hashash
Background: Up to a third of inflammatory bowel disease) patients show primary nonresponse to antitumor necrosis factor (anti-TNF) biological therapy, and of those who respond, up to 40% develop secondary loss of response (LOR). Therapeutic drug monitoring (TDM) plays a crucial role in assessing patients with LOR to guide therapy by giving more of the drug or switching to a different biological agent
-
5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules? Inflamm. Intest. Dis. Pub Date : 2021-09-03 Hans Herfarth, Stephan R. Vavricka
Background: Due to the increased incidence of colorectal cancer in inflammatory bowel diseases (IBDs), the value of chemoprevention for this patient group has been repeatedly debated in the past decade. This review describes available evidence and the current recommendations for chemoprevention in national and international guidelines IBD guidelines. Summary: 5-Aminosalicylic acid (5-ASA) compounds
-
Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility Loci Inflamm. Intest. Dis. Pub Date : 2021-09-02 Kasumi Hishinuma, Rintaro Moroi, Daisuke Okamoto, Yusuke Shimoyama, Masatake Kuroha, Hisashi Shiga, Yoichi Kakuta, Yoshitaka Kinouchi, Atsushi Masamune
Background: New therapeutic agents, including biologics and small-molecule drugs, are widely used to treat ulcerative colitis (UC). This study evaluates long-term prognosis in Japanese patients treated with these agents and the association between prognosis and genetic susceptibility to UC. Methods: We evaluated surgery-free rates using the Kaplan-Meier method in the total cohort and in patients treated
-
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients Inflamm. Intest. Dis. Pub Date : 2021-08-26 Manuel Sutter, Petr Hruz, Jan Hendrik Niess
Background: TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in #x3e;30% of patients with inflammatory bowel disease (IBD). Whether high serum CK levels are a specific effect of treatment with TNF inhibitors has not been studied in detail. CK levels were therefore compared between infliximab- and vedolizumab-treated
-
Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication? Inflamm. Intest. Dis. Pub Date : 2021-08-18 Ala I. Sharara, Maher Malaeb, Matthias Lenfant, Marc Ferrante
Background: Endoscopic remission is an increasingly recognized important therapeutic endpoint in the management of patients with UC. Summary: The Mayo Endoscopic Score (MES) remains the most common endoscopic index recommended in guidelines and widely used in clinical trials and in clinical practice. The MES is easy, simple, and practical but is suboptimal at providing an accurate depiction of segmental
-
Stopping Anti-TNF in CD Remitters: Cons Inflamm. Intest. Dis. Pub Date : 2021-08-10 Taku Kobayashi
Crohn’s disease may cause a life-long disease burden in many aspects due to its progressive nature. A large proportion of refractory patients have been benefiting from scheduled maintenance anti-TNF treatment; therefore, strategy to stop anti-TNF agents in Crohn’s disease is not widely conducted. There have been observational studies demonstrating that approximately half of the patients relapse within
-
A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis Inflamm. Intest. Dis. Pub Date : 2021-07-19 Cheryl de Vallière, Katharina Bäbler, Philipp Busenhart, Marlene Schwarzfischer, Chiaki Maeyashiki, Cordelia Schuler, Kirstin Atrott, Silvia Lang, Marianne R. Spalinger, Michael Scharl, Pedro A. Ruiz-Castro, Martin Hausmann, Gerhard Rogler
Background and Aims: Local extracellular acidification is associated with several conditions, such as ischemia, cancer, metabolic disease, respiratory diseases, and inflammatory bowel disease (IBD). Several recent studies reported a link between IBD and a family of pH-sensing G protein-coupled receptors. Our previous studies point to an essential role for OGR1 (GPR68) in the modulation of intestinal
-
Surgical Techniques and Risk of Postoperative Recurrence in CD: A Game Changer? Inflamm. Intest. Dis. Pub Date : 2021-05-21 Gaetano Luglio, Toru Kono
Background: Since its first description, the role of surgery in Crohn’s disease (CD) has always been controversial; in fact, it has been mainly considered as a gastroenterological disease for long time. Nevertheless, despite great advances in medical therapy, up to 70–80% of patients with CD will require surgery in their lifetime and up to 30% of them will undergo repeated surgeries due to recurrences
-
Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn’s Disease: Hard Sell or a Revolutionary New Norm? Inflamm. Intest. Dis. Pub Date : 2021-05-19 Beatriz Yuki Maruyama, Christopher Ma, Remo Panaccione, Paulo Gustavo Kotze
Background: Despite reductions in surgical rates that have been observed with earlier use of biological therapy, surgery still constitutes an important tool in the therapeutic armamentarium in Crohn’s disease (CD), particularly in patients with stenotic and penetrating phenotypes. In these scenarios, early surgical intervention is recommended, as bowel damage is present and irreversible, leading to
-
Faecal Inflammatory Biomarkers and Gastrointestinal Symptoms after Bariatric Surgery: A Longitudinal Study Inflamm. Intest. Dis. Pub Date : 2021-04-14 Floris Westerink, Inge Huibregtse, Marieke De Hoog, Sjoerd Bruin, Eelco Meesters, Desiderius Brandjes, Victor Gerdes
Background: Bariatric surgery induces various gastrointestinal (GI) modifications. We performed the first study longitudinally assessing the effect of bariatric surgery on faecal inflammatory biomarker levels and its relation with GI complaints. Method: Faecal calprotectin, lactoferrin, and calgranulin-C levels were determined in 41 patients (34 Roux-en-Y [RYGB], 7 sleeves) before and at 6–16 weeks
-
Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis Inflamm. Intest. Dis. Pub Date : 2021-04-13 Atsushi Yoshida, Katsuyoshi Matsuoka, Fumiaki Ueno, Toshio Morizane, Yutaka Endo, Toshifumi Hibi
Background: Anti-tumor necrosis factor-α (TNF-α) agents are effective for moderately to severely active ulcerative colitis (UC). Nonetheless, a proportion of patients fail to respond to these agents as therapy for induction of remission. Recent studies indicated that perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) may predict response to anti-TNF-α agents in UC patients. However, whether
-
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results Inflamm. Intest. Dis. Pub Date : 2021-04-13 Rebecca Sagar, Marco V. Lenti, Tanya Clark, Helen J. Rafferty, David J. Gracie, Alexander C. Ford, Anthony O’Connor, Tariq Ahmad, P. John Hamlin, Christian P. Selinger
Background: Therapeutic drug monitoring (TDM) of infliximab (IFX) trough levels and anti-drug antibodies in conjunction with symptoms, disease history, and investigations can aid decision-making. This study evaluated 1-year outcomes of patients with decisions that were altered on the basis of TDM results, in order to investigate whether outcomes from TDM-based decisions to adjust or stop IFX treatment
-
Hypoxia Reduces the Transcription of Fibrotic Markers in the Intestinal Mucosa Inflamm. Intest. Dis. Pub Date : 2021-03-29 Simona Simmen, Max Maane, Sarah Rogler, Katherina Baebler, Silvia Lang, Jesus Cosin-Roger, Kirstin Atrott, Isabelle Frey-Wagner, Partick Spielmann, Roland H. Wenger, Bruce Weder, Jonas Zeitz, Stephan R. Vavricka, Gerhard Rogler, Cheryl de Vallière, Martin Hausmann, Pedro A. Ruiz
Introduction: Intestinal fibrosis, characterized by excessive deposition of extracellular matrix proteins, is a common and severe clinical complication of inflammatory bowel disease (IBD). However, the mechanisms underlying fibrosis remain elusive, and currently, there are limited effective pharmacologic treatments that target the development of fibrosis. Hypoxia is one of the key microenvironmental
-
Real-World Experience of Endoscopic Submucosal Dissection for Ulcerative Colitis-Associated Neoplasia Inflamm. Intest. Dis. Pub Date : 2021-03-18 Akira Matsui, Shu Hoteya, Junnosuke Hayasaka, Satoshi Yamashita, Yorinari Ochiai, Yugo Suzuki, Yumiko Fukuma, Takayuki Okamura, Yutaka Mitsunaga, Masami Tanaka, Kousuke Nomura, Nobuhiro Dan, Hiroyuki Odagiri, Daisuke Kikuchi
Introduction: Patients with ulcerative colitis (UC) have an increased risk of colorectal cancer. Some studies have recently investigated endoscopic resection of UC-associated neoplasia (UCAN), but the indications for endoscopic resection of UCAN remain controversial. This study sought to clarify the problems encountered in endoscopic submucosal dissection (ESD) for UCAN. Methods: Seventeen lesions
-
Physical Activity in Patients with Inflammatory Bowel Disease: A Cross-Sectional Study Inflamm. Intest. Dis. Pub Date : 2021-02-24 Georgina Fagan, Hamish Osborne, Michael Schultz
Introduction and Objective: Despite the known benefits of physical activity in the management of chronic diseases, the use of exercise as a treatment is relatively underemployed, with many patients reporting their disease to be a barrier. This study aimed to assess physical activity levels, attitudes, and barriers towards exercise in a cohort of patients with inflammatory bowel disease (IBD). In addition
-
Elevated Faecal Calprotectin in Patients with a Normal Colonoscopy: Does It Matter in Clinical Practice? A Retrospective Observational Study Inflamm. Intest. Dis. Pub Date : 2021-02-17 Henrik Hovstadius, David Lundgren, Pontus Karling
Introduction: Faecal calprotectin (FC) is commonly used as a diagnostic tool for patients with gastrointestinal (GI) symptoms. However, there is uncertainty in daily clinical practice how to interpret an elevated FC in patients with a normal colonoscopy. We investigated if patients with a normal colonoscopy but with an elevated FC more often were diagnosed with a GI disease in a 3-year follow-up period
-
What Are the Most Challenging Aspects of Inflammatory Bowel Disease? An International Survey of Gastroenterologists Comparing Developed and Developing Countries Inflamm. Intest. Dis. Pub Date : 2021-02-05 Richard B. Gearry, Andrew M. McCombie, Morten Vatn, David T. Rubin, Flavio Steinwurz, Edward V. Loftus, Wolfgang Kruis, Curt Tysk, Jean-Frederic Colombel, Siew C. Ng, Gert Van Assche, Charles N. Bernstein, International Organization for the Study of Inflammatory Bowel Diseases and the World Gastroenterology Organization
Background and Aims: As inflammatory bowel disease (IBD) becomes more prevalent, the challenges that gastroenterologists face in managing these patients evolve. We aimed to describe the most important challenges facing gastroenterologists from around the world and compare these between those working in developed and developing countries. Methods: An online questionnaire was developed, and a link distributed
-
Vedolizumab in Inflammatory Bowel Disease: West versus East Inflamm. Intest. Dis. Pub Date : 2021-01-27 Prasanta Debnath, Pravin M. Rathi
Background: Vedolizumab is a humanized immunoglobulin G1 monoclonal antibody, which binds to α4β7 integrin on T lymphocytes, thus disturbing the interaction with mucosal vascular addressin cell adhesion molecule 1 on the intestinal endothelial cells to interfere with lymphocyte trafficking to the gut. Summary: Vedolizumab is a safe and effective drug to induce and maintain clinical remission in patients
-
Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn’s Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany Inflamm. Intest. Dis. Pub Date : 2020-12-18 Niels Teich, Michael Bläker, Frank Holtkamp-Endemann, Eric Jörgensen, Andreas Stallmach, Susanne Hohenberger
Introduction: Infliximab (IFX) therapy is efficacious for inducing and maintaining symptomatic remission in patients with Crohn’s disease (CD), but whether this benefit results in reduced hospitalization rates and therefore may improve patients’ quality of life in an economically sensible way is conflicting so far. Methods: We conducted a noninterventional, multicenter, open-label, prospective study
-
Are We Overradiating Patients with Irritable Bowel Syndrome? Inflamm. Intest. Dis. Pub Date : 2020-12-09 Yousaf B. Hadi, Adnan Aman Khan, Syeda F.Z. Naqvi, Salman Khan, Jesse Thompson, Justin T. Kupec
Introduction: Protracted exposures to small doses of radiation, even cumulative effective doses (CED) as low as 50–100 mSv, may increase the risk for malignancy. Medical radiation exposure has not been rigorously examined for patients with irritable bowel syndrome (IBS). We examined medical radiation exposure in patients with IBS at a tertiary care center in the USA. Methods: Patients diagnosed with
-
Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients Inflamm. Intest. Dis. Pub Date : 2020-11-20 Ilana Reinhold, Sena Blümel, Jens Schreiner, Onur Boyman, Jan Bögeholz, Marcus Cheetham, Gerhard Rogler, Luc Biedermann, Michael Scharl
Background and Aims: The majority of patients treated with anti-tumor necrosis factor (TNF) therapy develop anti-drug antibodies (ADAs), which might result in loss of treatment efficacy. Strict guidelines on measuring trough levels (TLs) and ADA in clinical routine do not exist. To provide real-world data, we took advantage of our tertiary inflammatory bowel disease (IBD) center patient cohort and